# Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)

> **NCT02021032** · PHASE4 · UNKNOWN · sponsor: **Medifocus, Inc.** · enrollment: 250 (estimated)

## Conditions studied

- Benign Prostate Hyperplasia

## Interventions

- **DEVICE:** Prolieve

## Key facts

- **NCT ID:** NCT02021032
- **Lead sponsor:** Medifocus, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-02
- **Primary completion:** 2018-02
- **Final completion:** 2018-08
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2015-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02021032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02021032, "Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02021032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*